Delayed educational reminders for long-term medication adherence in ST-elevation myocardial infarction (DERLA-STEMI): Protocol for a pragmatic, cluster-randomized controlled trial

Implementation Science

Madhu K Natarajan⁶  Merrick Zwarenstein¹  Monica Taljaard²  Holly Witteman⁵  Jeremy M Grimshaw⁴  Jon-David Schwalm⁶  Noah M Ivers³ 

[1] Institute for Clinical Evaluative Sciences, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada;Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa Hospital, Civic Campus, 1053 Carling Avenue, Ottawa, Ontario, Canada;Family Practice Health Centre, Women’s College Research Institute, Women’s College Hospital, 76 Grenville Ave Toronto, Toronto, Ontario, Canada;Ottawa Hospital - General Campus, Centre for Practice-Changing Research, 501 Smyth Road, Ottawa, Ontario, Canada;Center for Bioethics & Social Sciences in Medicine, Department of Internal Medicine, University of Michigan, 300 North Ingalls Ann Arbor, Michigan, USA;Department of Medicine, Division of Cardiology, McMaster University/Hamilton Health Sciences, 237 Barton Street, East Hamilton, Ontario, Canada

关键词: Reminders;    Medication adherence;    Randomized trial;   

Others  :  815376
DOI  :  10.1186/1748-5908-7-54

 received in 2012-04-15, accepted in 2012-05-15,  发布年份 2012

【 授权许可】

   
2012 Ivers et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Murray CJ, Lopez AD: Evidence-based health policy–lessons from the Global Burden of Disease Study. Science 1996, 274(5288):740-743.
• [2]National Cholesterol Education Program (NCEP) Expert Panel on Detection: Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106(25):3143-3421.
• [3]Smith SC Jr: Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, Grundy SM, Hiratzka LF, Jones DW, Lloyd-Jones DM, Minissian M, Mosca L, Peterson ED, Sacco RL, Spertus J, Stein JH, Taubert KA, World Heart Federation and the Preventive Cardiovascular Nurses Association: AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011, 124(22):2458-2473.
• [4]Hippisley-Cox J, Coupland C: Effect of statins on the mortality of patients with ischaemic heart disease: population based cohort study with nested case–control analysis. Heart 2006, 92(6):752-758.
• [5]Wijeysundera HC, Machado M, Farahati F, Wang X, Witteman W, van der Velde G, Tu JV, Lee DS, Goodman SG, Petrella R, O'Flaherty M, Krahn M, Capewell S: Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994–2005. JAMA 2010, 303(18):1841-1847.
• [6]Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O’Donnell C, Kittner S, Lloyd-Jones D, Goff DC Jr, Hong Y, Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller S, Wilson M, Wolf P: American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006, 113(6):e85-151.
• [7]Myerburg RJ, Kessler KM, Castellanos A: Sudden cardiac death: epidemiology, transient risk, and intervention assessment. Ann Intern Med 1993, 119(12):1187-1197.
• [8]Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, Hochman JS, Krumholz HM, Lamas GA, Mullany CJ, Pearle DL, Sloan MA, Smith SC Jr: 2004 Writing Committee Members, Anbe DT, Kushner FG, Ornato JP, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW: 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008, 117(2):296-329.
• [9]Fitchett DH, Theroux P, Brophy JM, Cantor WJ, Cox JL, Gupta M, Kertland H, Mehta SR, Welsh RC, Goodman SG: Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment--part 2: ST-segment elevation myocardial infarction. Can J Cardiol 2011, 27((Suppl A)):402-412.
• [10]Tu JV, Donovan LR, Lee DS, Wang JT, Austin PC, Alter DA, Ko DT: Effectiveness of public report cards for improving the quality of cardiac care: the EFFECT study: a randomized trial. JAMA 2009, 302(21):2330-2337.
• [11]Ahmad M, Schwalm JD, Velianou JL, Natarajan MK: Impact of routine in-hospital assessment of low-density lipoprotein levels and standardized orders on statin therapy in patients undergoing percutaneous coronary interventions. J Invasive Cardiol 2005, 17(10):518-520.
• [12]Newby LK, LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER, Muhlbaier LH, Califf RM: Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006, 113(2):203-212.
• [13]Hudson M, Richard H, Pilote L: Parabolas of medication use and discontinuation after myocardial infarction–are we closing the treatment gap? Pharmacoepidemiol Drug Saf 2007, 16(7):773-785.
• [14]Shah ND, Dunlay SM, Ting HH, Montori VM, Thomas RJ, Wagie AE, Roger VL: Long-term medication adherence after myocardial infarction: experience of a community. Am J Med 2009, 122(10):e7-13. 961.
• [15]Rasmussen JN, Chong A, Alter DA: Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007, 297(2):177-186.
• [16]Shalev V, Chodick G, Silber H, Kokia E, Jan J, Heymann AD: Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med 2009, 169(3):260-268.
• [17]Rublee DA, Chen SY, Mardekian J, Wu N, Rao P, Boulanger L: Evaluation of cardiovascular morbidity associated with adherence to atorvastatin therapy. Am J Ther 2012, 19(1):24-32.
• [18]Rodriguez LA, Cea-Soriano L, Martin-Merino E, Johansson S: Discontinuation of low dose aspirin and risk of myocardial infarction: case–control study in UK primary care. BMJ 2011, 343:4094.
• [19]Brown MT, Bussell JK: Medication adherence: WHO cares? Mayo Clin Proc 2011, 86(4):304-314.
• [20]Bosworth HB, Granger BB, Mendys P, Brindis R, Burkholder R, Czajkowski SM, Daniel JG, Ekman I, Ho M, Johnson M, Kimmel SE, Liu LZ, Musaus J, Shrank WH: Whalley Buono E, Weiss K, Granger CB: Medication adherence: a call for action. Am Heart J 2011, 162(3):412-424.
• [21]Kreps GL, Villagran MM, Zhao X, McHorney CA, Ledford C, Weathers M, Keefe B: Development and validation of motivational messages to improve prescription medication adherence for patients with chronic health problems. Patient Educ Couns 2011, 83(3):375-381.
• [22]Gill PS, Quirke TP, Mant JW, Allan TF: The use of lipid-lowering drugs across ethnic groups in the secondary prevention of ischaemic heart disease: analysis of cross-sectional surveys in England. Br J Gen Pract 2004, 54(503):442-443.
• [23]Chiu M, Austin PC, Manuel DG, Tu JV: Comparison of cardiovascular risk profiles among ethnic groups using population health surveys between 1996 and 2007. CMAJ 2010, 182(8):E301-E310.
• [24]Rabi DM, Edwards AL, Svenson LW, Graham MM, Knudtson ML, Ghali WA: Alberta Provincial Project for Assessing Outcomes in Coronary Heart Disease Investigators: Association of median household income with burden of coronary artery disease among individuals with diabetes. Circ Cardiovasc Qual Outcomes 2010, 3(1):48-53.
• [25]Bagnall AJ, Yan AT, Yan RT, Lee CH, Tan M, Baer C, Polasek P, Fitchett DH, Langer A, Goodman SG: Canadian Acute Coronary Syndromes Registry II Investigators: Optimal medical therapy for non-ST-segment-elevation acute coronary syndromes: exploring why physicians do not prescribe evidence-based treatment and why patients discontinue medications after discharge. Circ Cardiovasc Qual Outcomes 2010, 3(5):530-537.
• [26]Sud A, Kline-Rogers EM, Eagle KA, Fang J, Armstrong DF, Rangarajan K, Otten RF, Stafkey-Mailey DR, Taylor SD, Erickson SR: Adherence to medications by patients after acute coronary syndromes. Ann Pharmacother 2005, 39(11):1792-1797.
• [27]Ab E, Denig P, van Vliet T, Dekker JH: Reasons of general practitioners for not prescribing lipid-lowering medication to patients with diabetes: a qualitative study. BMC Fam Pract 2009, 10:24. BioMed Central Full Text
• [28]Hickling J, Rogers S, Nazareth I: Barriers to detecting and treating hypercholesterolaemia in patients with ischaemic heart disease: primary care perceptions. Br J Gen Pract 2005, 55(516):534-538.
• [29]Bell CM, Brener SS, Gunraj N, Huo C, Bierman AS, Scales DC, Bajcar J, Zwarenstein M, Urbach DR: Association of ICU or hospital admission with unintentional discontinuation of medications for chronic diseases. JAMA 2011, 306(8):840-847.
• [30]Austin PC, Tu JV, Ko DT, Alter DA: Factors associated with the use of evidence-based therapies after discharge among elderly patients with myocardial infarction. CMAJ 2008, 1790(9):901-908.
• [31]Ryan R, Santesso N, Hill S, Lowe D, Kaufman C, Grimshaw J: Consumer-oriented interventions for evidence-based prescribing and medicines use: an overview of systematic reviews. Cochrane Database Syst Rev 2011., 5(5) CD007768.
• [32]Chong WW, Aslani P, Chen TF: Effectiveness of interventions to improve antidepressant medication adherence: a systematic review. Int J Clin Pract 2011, 65(9):954-975.
• [33]Al-Aqeel S, Al-Sabhan J: Strategies for improving adherence to antiepileptic drug treatment in patients with epilepsy. Cochrane Database Syst Rev 2012., 1(1) CD008312.
• [34]Schedlbauer A, Davies P, Fahey T: Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev 2010., 3CD004371.
• [35]Kunz R, Vist G, Oxman AD: Randomisation to protect against selection bias in healthcare trials. Cochrane Database Syst Rev 2007., 2(2) MR000012.
• [36]Smith DH, Kramer JM, Perrin N, Platt R, Roblin DW, Lane K, Goodman M, Nelson WW, Yang X, Soumerai SB: A randomized trial of direct-to-patient communication to enhance adherence to beta-blocker therapy following myocardial infarction. Arch Intern Med 2008, 68(5):477-483. discussion 483; quiz 447.
• [37]Feder G, Griffiths C, Eldridge S, Spence M: Effect of postal prompts to patients and general practitioners on the quality of primary care after a coronary event (POST): randomised controlled trial. BMJ 1999, 318(7197):1522-1526.
• [38]McAlister FA, Fradette M, Majumdar SR, Williams R, Graham M, McMeekin J, Ghali WA, Tsuyuki RT, Knudtson ML, Grimshaw J: The Enhancing Secondary Prevention in Coronary Artery Disease trial. CMAJ 2009, 181(12):897-904.
• [39]Ahmad M, Schwalm JD, Velianou JL, Pericak D, Natarajan MK: Comparison of one-year clinical outcomes with paclitaxel-eluting stents versus bare metal stents in everyday practice. Can J Cardiol 2008, 24(10):771-775.
• [40]Schwalm JD, Ahmad M, Velianou JL, Pericak D, Natarajan MK: Long-term outcomes with paclitaxel-eluting stents versus bare metal stents in everyday practice: a Canadian experience. Can J Cardiol 2010, 26(2):e40-e44.
• [41]Kripalani S, LeFevre F, Phillips CO, Williams MV, Basaviah P, Baker DW: Deficits in communication and information transfer between hospital-based and primary care physicians: implications for patient safety and continuity of care. JAMA 2007, 297(8):831-841.
• [42]Treweek S, Zwarenstein M: Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials 2009, 10:37. BioMed Central Full Text
• [43]Nolan T, Berwick DM: All-or-none measurement raises the bar on performance. JAMA 2006, 295(10):1168-1170.
• [44]Morisky DE, Green LW, Levine DM: Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986, 24(1):67-74.
• [45]Shalansky SJ, Levy AR, Ignaszewski AP: Self-reported Morisky score for identifying nonadherence with cardiovascular medications. Ann Pharmacother 2004, 38(9):1363-1368.
• [46]Bermingham M, Hayden J, Dawkins I, Miwa S, Gibson D, McDonald K, Ledwidge M: Prospective analysis of LDL-C goal achievement and self-reported medication adherence among statin users in primary care. Clin Ther 2011, 33(9):1180-1189.
• [47]Steiner JF, Prochazka AV: The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997, 50(1):105-116.
• [48]Donner A, Klar N: Design and Analysis of Cluster Randomization Trials in Health Research. New York: Oxford University Press; 2000.
• [49]Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R: Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366(9493):1267-1278.